JO
QNCX icon

John Overdeck’s Quince Therapeutics QNCX Stock Holding History

John Overdeck’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-356
Closed -$7.22K – 5349
2026
Q1 		$7.22K Sell
356
-549
-61% -$110K ﹤0.01% 4537
2025
Q4 		$606K Buy
905
+830
+1,107% +$418K ﹤0.01% 3205
2025
Q3 		$24.6K Sell
75
-12
-14% -$4K ﹤0.01% 3587
2025
Q2 		$28.7K Sell
87
-119
-58% -$27.2K ﹤0.01% 3101
2025
Q1 		$54.7K Buy
206
+54
+36% +$16.5K ﹤0.01% 3035
2024
Q4 		$56.7K Buy
+152
New +$45.7K ﹤0.01% 3031
2024
Q1 		– Sell
-66
Closed -$13.8K – 3319
2023
Q4 		$13.8K Sell
66
-32
-33% -$6.41K ﹤0.01% 3065
2023
Q3 		$22K Sell
98
-250
-72% -$65.3K ﹤0.01% 2866
2023
Q2 		$105K Sell
348
-287
-45% -$89.3K ﹤0.01% 2753
2023
Q1 		$198K Sell
635
-1,701
-73% -$333K ﹤0.01% 2558
2022
Q4 		$298K Sell
2,336
-152
-6% -$25.4K ﹤0.01% 2251
2022
Q3 		$662K Sell
2,488
-64
-3% -$24.4K ﹤0.01% 1646
2022
Q2 		$1.13M Buy
2,552
+171
+7% +$121K ﹤0.01% 1490
2022
Q1 		$2.95M Sell
2,381
-606
-20% -$825K 0.01% 1173
2021
Q4 		$7.54M Buy
2,987
+2,622
+718% +$16M 0.02% 952
2021
Q3 		$6.7M Buy
365
+184
+102% +$2.93M 0.02% 1015
2021
Q2 		$1.92M Sell
181
-7
-4% -$58.7K ﹤0.01% 1907
2021
Q1 		$1.35M Buy
188
+86
+84% +$619K ﹤0.01% 2038
2020
Q4 		$564K Buy
102
+39
+62% +$346K ﹤0.01% 2425
2020
Q3 		$627K Buy
63
+9
+17% +$81.9K ﹤0.01% 2071
2020
Q2 		$501K Buy
+54
New +$495K ﹤0.01% 1993

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

John Overdeck's QNCX Position: Q2 2026 in Review

John Overdeck sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 356 shares — an estimated $7.22K sold.

John Overdeck first reported a position in QNCX in Q2 2020 and held it in 21 quarters. The position peaked at $7.54M in Q4 2021. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • John Overdeck reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 356 Quince Therapeutics shares in Q2 2026, an estimated $7.22K.
  • John Overdeck first reported a position in Quince Therapeutics in Q2 2020 and held it in 21 quarters.
  • John Overdeck's Quince Therapeutics position peaked at $7.54M in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.